Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paragol
- Development stage
- Unknown
- Lead developer
- Streuli Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Paragol (also marketed as Paragol N) is an oral emulsion developed and marketed by Streuli Pharma. Its active ingredient is mineral oil (liquid paraffin), which acts as a lubricant laxative in the gastrointestinal tract. Paragol is indicated for the short-term treatment of constipation, as well as for conditions where facilitated defecation is beneficial, such as hemorrhoids or anal fissures. It works by coating the stool and the intestinal wall, reducing friction and preventing water reabsorption, which softens the stool and eases its passage.
- Brand names
- ParagolParagol N
Beyond the preview
Go deeper on Paragol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paragol.